One day before comments closed on the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights, published by the National Institute of Standards & Technology (NIST) and the Department of Commerce last month, the Department of Health and Human Services (HHS) denied an appeal of a decision not to march in on the blockbuster prostate cancer drug, Xtandi®.
Recent Posts
- Reddit Dubs Perplexity AI and Data Scraping Companies ‘Would-Be Bank Robbers’
- CAFC Gives Centripetal Another Shot at PTAB in Case Tied to APJ’s Alleged Bias
- Undermining Innovation: The Consequences of Closing the Rocky Mountain Regional USPTO Office
- Does the 2025 Version of PERA Indirectly Sanction Judicially Created, Non-Statutory ODP?
- Squires Takes Over All IPR Institution Decisions in Memo to PTAB Judges